Tag Archives: front page

Fujitsu Highlights POLARISqb as a Tech Innovator Driving Digital Transformation

Last year Polarisqb  began our journey to revolutionize the world of drug discovery by using the most advanced computers on the planet to perform in silico protein targeting at speeds never before thought possible. One of our most important partners in this new venture was Fujitsu, who had developed the most sophisticated Digital Annealing Computer on the planet.

PolarisQB was featured as an innovative customer in Fujitsu's eBook on driving digital transformation.

Using this machine that can reach near quantum speeds we designed our Tachyon platform that is able to perform complex simulations of molecular and chemical reactions that provide crucial information to scientists and researchers who are working to develop treatments and cures for diseases that affect billions of people around the globe.

Fujitsu has recognized this work in an eBook titled Driving Digital Transformation with our Customers along with five other companies that are utilizing high powered computers to drive innovation in the fields of logistics, finance, fashion, food supply, and aerospace. Read more about our work and the other customers who made the list below.

Fujitsu: Driving Digital Transformation With Our Customers

Auransa and POLARISqb Enter Research Collaboration to find Treatments for Neglected Women’s Diseases
PALO ALTO, Calif. and DURHAM, N.C., June 04, 2021 /PRNewswire/ -- Auransa, Inc., an artificial intelligence (AI) company developing precision medicines in areas of unmet medical needs, and Polaris Quantum Biotech (POLARISqb), a quantum drug design company, announced a research collaboration addressing therapeutics for neglected diseases disproportionately affecting women.  The partnership seeks to discover treatments that may tackle…
Read more
PolarisQB Announce Hiring of Pharmacologist Ian Reynolds
Polarisqb  is proud to add Dr. Ian Reynolds, a world renowned expert in pharmacology, as an advisor to the company. Dr. Ian Reynolds is an experienced pharmaceutical executive who has been recognized for his work in small molecule drug discovery and has helped a number of academic researchers translate into the world of biotech research…
Read more
PM 360 Recognizes POLARISqb as a 2020 Innovative Startup

PM 360 is one of the leading magazines in the pharmaceutical marketing world, with an audience of marketing decision makers in the pharmaceutical, biotech, and medical device industries. Published monthly, the magazine focuses on leadership as well as, "issues that directly impact critical decision making,including: planning and implementation of cutting edge strategies, trends, the latest technological advances," in their writing.

This year, POLARISqb was honored to be one of eight companies that were named "Innovative Startups" by the magazine, along with Evozyne, Steady Shot, ImmunAI, Exocel, wePool, Conversation Health and Theraneutrics. These companies are working with some of the most advanced technologies such as artificial intelligence, nanotechnology, and synthetic biotech to address medical issues from diabetes to COVID-19, but POLARISqb stands alone as the sole quantum application selected to the list. Having developed a quantum application for designing drugs, we continue to pursue a vastly greater understanding of our chemical universe, identifying molecules that will become treatments and cures for all diseases for all people. Advancements in quantum computers technology continue to speed our work towards a quantum-based platform that provides chemical simulations at many times the speed of current traditional systems.

We are proud to be recognized for our work and innovation in drug discovery for biopharma applications by one of the leading publications on pharmaceutical marketing, a list that has in the past included companies such as H1 who went on to raise over $71M in capital funding and OM1 who raised over $86M, and Sema4 which raised over $240M. POLARISqb looks to be the next in their line of success, and the first quantum alumni of the list to revolutionize the world of biotech and pharmaceuticals.